The formulation is designed to remove dependence on both animal serum and donor-derived human platelet supplements during cell therapy manufacturing. The launch comes as both markets continue to deepen their advanced therapy ecosystems. Behind every cell therapy breakthrough is a production process that must work repeatedly, not only once. AuctuPrime is a manufacturing input used during cell culture and is not itself a cell therapy product. Through its collaboration with AuctuCel, Sperikon contributes to the development of next-generation chemically defined manufacturing platforms.